AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27768923
Drug: Triplet hepatic
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triplet hepatic artery infusion (HAI) and intravenous cetuximab (500 mg/m² cetuximab, 180 mg/m² irinotecan)
Trial: 27768923
Drug: Triplet hepatic
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triplet hepatic artery infusion (HAI) and intravenous cetuximab
Trial: 27771496
Drug: Rituximab 250
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab 250 mg (days -21 and -14)
Trial: 27771496
Drug: Fludarabine 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine 30 mg/m2
Trial: 27771544
Drug: Nilotinib 400mg
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nilotinib 400mg twice daily for 24 months
Trial: 27771610
Drug: Tivozanib (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tivozanib (1.5 mg daily, 3 weeks on 1 week off, 28-day cycle)
Trial: 27774033
Drug: Inhaled capsaicin
RxNorm normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled capsaicin solution challenge
Trial: 27774059
Drug: Music Upper
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Music Upper Limb Therapy-Integrated (MULT-I), 45-min intervention, twice a week for 6 weeks
Trial: 27774495
Drug: OnabotulinumtoxinA treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OnabotulinumtoxinA treatments
Trial: 27775823
Drug: CALM-CBT (Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CALM-CBT (Cognitive Behavioral Therapy)
Trial: 27775823
Drug: CBT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT plus medication management
Trial: 27775823
Drug: Higher CBT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher CBT dose
Trial: 27776521
Drug: Artemether-lumefantrine (AL)
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemether-lumefantrine (AL) administered under direct observation with a fat intake consisting of ready-to-use therapeutic food (RUTF - Plumpy'Nut®), twice daily during 3 days.
Trial: 27777606
Drug: Diet Rite
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet Rite Cola™ (18 mg sucralose, 18 mg acesulfame-potassium, 57 mg aspartame)
Trial: 27777606
Drug: NNS in
RxNorm normalized name: trastuzumab-anns Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NNS in water (0 mg, 68 mg, 170 mg, 250 mg sucralose)
Trial: 27777612
Drug: Evidence-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evidence-based treatment of panic disorder
Trial: 27778193
Drug: Sodium Oxybate
RxNorm normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium Oxybate (SXB) 9 g/night
Trial: 27778639
Drug: Droxidopa (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droxidopa (300 mg, 3 times a day)
Trial: 27778639
Drug: Treatment-naive conditions
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-naive conditions
Trial: 27779248
Drug: Intravenous busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous busulfan (Bu)
Trial: 27780903
Drug: Successful reperfusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Successful reperfusion (defined as modified Treatment in Cerebral Ischemia grade of 2b to 3)
Trial: 27781135
Drug: Brexpiprazole 1-3
RxNorm normalized name: brexpiprazole 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brexpiprazole 1-3 mg/day
Trial: 27782373
Drug: Sofosbuvir/simeprevir plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir/simeprevir plus flat dose ribavirin (800 mg/d) for 12 weeks
Trial: 27785036
Drug: Digital medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital medicine system (DMS) with sensor-embedded tablets of aripiprazole, 8-week treatment.
Trial: 27787664
Drug: Interferon (IFN)-free
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon (IFN)-free treatment
Trial: 27787778
Drug: Alogliptin (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin (12.5 mg and 25 mg doses)
Trial: 27789147
Drug: Pfs25H-EPA/Alhydrogel® vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pfs25H-EPA/Alhydrogel® vaccine candidate
Trial: 27789517
Drug: Adenosine diphosphate
RxNorm normalized name: Adenosine diphosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine diphosphate receptor inhibitors (ADPri) therapy
Trial: 27789517
Drug: Early cessation
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early cessation of ADPri therapy
Trial: 27789678
Drug: INCB039110 (selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCB039110 (selective JAK1 inhibitor)
Trial: 27791128
Drug: Vaccination with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccination with peptide 1 or 7 in combination with RFASE
Trial: 27791128
Drug: Antibodies raised
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibodies raised with peptides 15 and 20
Trial: 27791347
Drug: PF-06651600 (JAK3-selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06651600 (JAK3-selective inhibitor)
Trial: 27793850
Drug: DMUC5754A (0.3-3.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMUC5754A (0.3-3.2 mg/kg every 3 weeks)
Trial: 27793850
Drug: DMUC5754A (0.8-1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMUC5754A (0.8-1.6 mg/kg weekly)
Trial: 27796540
Drug: Elotuzumab monotherapy
RxNorm normalized name: elotuzumab
DrugBank: Elotuzumab (DB06317)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Elotuzumab monotherapy (10 or 20 mg/kg)
Trial: 27796740
Drug: ASP0113 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASP0113 (5 mg, five doses at intervals before and after HCT)
Trial: 27797988
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of physical activity and normocaloric diet
Trial: 27798346
Drug: Daily eating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily eating episodes (mean ± SD: 4.2 ± 1.3 times/d)
Trial: 27798346
Drug: Daily eating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily eating episodes
Trial: 27798550
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg of TDF during labor (Cohort 1)
Trial: 27798550
Drug: 4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/kg dose on days 0, 3 and 5 (Cohort 2)
Trial: 27798550
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg maternal dose during labor, followed by 6 mg/kg infant dose on days 0, 3 and 5 (Cohort 3)
Trial: 27799204
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg efavirenz (single oral dose)
Trial: 27799230
Drug: Clopidogrel administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel administration for 7 days
Trial: 27799506
Drug: Dabrafenib and
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dabrafenib and NovoTTF-100A (Tumor Treatment Fields device)
Trial: 27799506
Drug: NovoTTF-100A (Tumor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NovoTTF-100A (Tumor Treatment Fields device) with concurrent radiation and chemotherapy (CCRT)
Trial: 27799945
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment at a fixed dose of 0.033 mg/kg/day for 260 weeks
Trial: 27799945
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment at a fixed dose of 0.067 mg/kg/day for 260 weeks
Trial: 27799945
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment (both doses)
Trial: 27799945
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment (high dose)
Trial: 27801315
Drug: JAK inhibitor
RxNorm normalized name: Janus-associated kinase (JAK) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JAK inhibitor ruxolitinib
Trial: 27801983
Drug: Hydrocortisone dosing
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone dosing frequency
Trial: 27803005
Drug: Vandetanib 300
RxNorm normalized name: vandetanib 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vandetanib 300 mg daily
Trial: 27805836
Drug: Lumacaftor/Ivacaftor (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumacaftor/Ivacaftor (200 mg lumacaftor/250 mg ivacaftor orally every 12 hours for 24 weeks)
Trial: 27811504
Drug: Observation after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observation after nephrectomy without adjuvant chemotherapy
Trial: 27812547
Drug: Inhaled sodium
RxNorm normalized name: Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled sodium nitrite at doses of 45 mg and 90 mg
Trial: 27812547
Drug: Inhaled sodium
RxNorm normalized name: Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled sodium nitrite
Trial: 27813195
Drug: D-mannose powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-mannose powder 1.5 grams twice daily for 16 weeks
Trial: 27814377
Drug: 7.5 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 μg of the homologous strain vaccine re-immunized at 6-months
Trial: 27814377
Drug: 30 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 μg alum-adjuvanted clade 2, A/Indonesia vaccine re-immunized at 22-months
Trial: 27814377
Drug: 30 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 μg alum-adjuvanted A/Vietnam vaccine
Trial: 27814709
Drug: Acupoint herbal
RxNorm normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint herbal plaster treatments (4 applications using moxibustion technique)
Trial: 27814709
Drug: Acupoint herbal
RxNorm normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint herbal plaster treatments
Trial: 27814763
Drug: Cost of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cost of delivering three doses of SP
Trial: 27815915
Drug: Adalimumab 40
RxNorm normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 40 mg every other week for 16 weeks
Trial: 27816492
Drug: Tremelimumab (3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tremelimumab (3.5 and 10mg/kg i.v.) every 4 weeks for 6 doses, followed by 3-monthly infusions until off-treatment criteria were met.
Trial: 27816492
Drug: Tremelimumab in
RxNorm normalized name: tremelimumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tremelimumab in combination with subtotal radiofrequency ablation or chemoablation.
Trial: 27816492
Drug: Tremelimumab in
RxNorm normalized name: tremelimumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tremelimumab in combination with tumor ablation.
Trial: 27821451
Drug: Auranofin, 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auranofin, 6 mg orally daily for 7 days
Trial: 27822376
Drug: Magnetic resonance-guided
RxNorm normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnetic resonance-guided high-intensity focused ultrasound (HIFU) treatment
Trial: 27825292
Drug: Acute spondylolysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute spondylolysis treatment
Trial: 27825340
Drug: Nurse-led telecoaching
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse-led telecoaching programme consisting of 5 monthly telephone sessions of +/- 30 min
Trial: 27825636
Drug: Cabozantinib 60
RxNorm normalized name: cabozantinib 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib 60 mg orally per day
Trial: 27827322
Drug: Adiponectin and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adiponectin and thigh subcutaneous adipose tissue in women without PCOS
Trial: 27828822
Drug: Fluorescence imaging
RxNorm normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluorescence imaging (FI) using indocyanine green (ICG) at 0.25 mg/kg IV-injected intraoperatively
Trial: 27828943
Drug: Selective PI3Kγ
RxNorm normalized name: Pi3k.delta.-in-2
DrugBank: Linperlisib (DB17235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective PI3Kγ inhibitor (IPI-549)
Trial: 27829430
Drug: Antibodies to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibodies to pRBC surface antigens
Trial: 27829430
Drug: Opsonizing antibody
RxNorm normalized name: Opsonizing antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opsonizing antibody
Trial: 27829430
Drug: Antibodies to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibodies to merozoite antigens and non-placental-binding IEs
Trial: 27829430
Drug: Antibodies to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibodies to placental-binding infected erythrocytes
Trial: 27830207
Drug: Interactive Binocular
RxNorm normalized name: Menin-mll interaction inhibitor ko 539
DrugBank: Ziftomenib (DB17171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interactive Binocular Treatment (I-BiT™) with patching
Trial: 27831501
Drug: Monoclonal antibody
RxNorm normalized name: Monoclonal antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibody (mAb) therapy
Trial: 27833752
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CPOT and BPS
Trial: 27834750
Drug: Patients deemed
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients deemed too good for intravenous tissue-type plasminogen activator
Trial: 27836022
Drug: LVAD therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LVAD therapy
Trial: 27836716
Drug: Brigatinib 180
RxNorm normalized name: brigatinib 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brigatinib 180 mg once daily
Trial: 27836716
Drug: Brigatinib 90
RxNorm normalized name: brigatinib 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brigatinib 90 mg once daily
Trial: 27836716
Drug: Brigatinib 180
RxNorm normalized name: brigatinib 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brigatinib 180 mg once daily with a 7 day lead-in at 90 mg
Trial: 27836860
Drug: Everolimus as
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus as primary therapy
Trial: 27842560
Drug: AposTherapy (biomechanical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AposTherapy (biomechanical treatment)
Trial: 27843120
Drug: Panobinostat 20
RxNorm normalized name: panobinostat 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panobinostat 20 mg in combination with bortezomib, thalidomide, and dexamethasone
Trial: 27843136
Drug: Rituximab (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (375 mg/m²) as part of high-dose methotrexate-based immuno-chemotherapy
Trial: 27843557
Drug: Walnut-included diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Walnut-included diet (56 g, 366 kcal per day)
Trial: 27843564
Drug: Prasugrel 10
RxNorm normalized name: prasugrel 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 10 mg/day maintenance dose (MD)
Trial: 27843564
Drug: Prasugrel 5
RxNorm normalized name: prasugrel 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 5 mg/day maintenance dose (MD)
Trial: 27843625
Drug: PRAME immunotherapeutic
RxNorm normalized name: PrameGel Reformulated Apr 2012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRAME immunotherapeutic (recPRAME) with AS15, 20 µg in cohort 1
Trial: 27843625
Drug: PRAME immunotherapeutic
RxNorm normalized name: PrameGel Reformulated Apr 2012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRAME immunotherapeutic (recPRAME) with AS15, 100 µg in cohort 2
Trial: 27843625
Drug: PRAME immunotherapeutic
RxNorm normalized name: PrameGel Reformulated Apr 2012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRAME immunotherapeutic (recPRAME) with AS15, 500 µg in cohort 3
Trial: 27846060
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated chimeric Japanese encephalitis vaccine booster dose
Trial: 27846821
Drug: 800 or
RxNorm normalized name: Acitak 800 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 or 1600 IU vitamin D3 with calcium (one or two tablets daily) for 10 months
Trial: 27846913
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (IC) with cisplatin, 5-fluorouracil, and docetaxel (TPF) plus concurrent chemoradiotherapy (CCRT)
Trial: 27847367
Drug: MenB-4C vaccine
RxNorm normalized name: meningococcal group B vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenB-4C vaccine
Trial: 27848065
Drug: Oral anticoagulant
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulant (OAC) therapies in patients with significant valvular disease (SVD)
Trial: 27848065
Drug: Oral anticoagulant
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulant (OAC) therapies in patients with non-significant valvular disease (NSVD)
Trial: 27848182
Drug: Elotuzumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elotuzumab (10 mg/kg, increased to 20 mg/kg if no DLTs), lenalidomide (25 mg orally), dexamethasone (28 mg orally plus 8 mg intravenously on elotuzumab days; 40 mg orally on non-elotuzumab days)
Trial: 27852119
Drug: Albiglutide 30
RxNorm normalized name: ALBIGLUTIDE 30MG/0.5ML INJ PEN 0.5ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albiglutide 30 mg plus a single OAD (sulfonylurea)
Trial: 27852119
Drug: Albiglutide 30
RxNorm normalized name: ALBIGLUTIDE 30MG/0.5ML INJ PEN 0.5ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albiglutide 30 mg plus a single OAD (glinide)
Trial: 27852119
Drug: Albiglutide 30
RxNorm normalized name: ALBIGLUTIDE 30MG/0.5ML INJ PEN 0.5ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albiglutide 30 mg plus a single OAD (other OADs)
Trial: 27852119
Drug: Albiglutide (uptitrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albiglutide (uptitrated to 50 mg after Week 4)
Trial: 27852260
Drug: Oral corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral corticosteroids for 2 weeks and budesonide/formoterol for 12 weeks
Trial: 27852260
Drug: Oral corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral corticosteroids for 2 weeks
Trial: 27852955
Drug: Rx (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rx (oral trimethoprim-sulfamethoxazole or minocycline plus oral rifampin; chlorhexidine mouthwash for 2 weeks; nasal mupirocin and chlorhexidine body wipes for 5 days; environmental decontamination for 21 days)
Trial: 27853379
Drug: Platinum-based chemotherapy
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum-based chemotherapy (with pemetrexed or gemcitabine)
Trial: 27855112
Drug: Caspofungin (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caspofungin (standard dose)
Trial: 27855624
Drug: Long-term PDE5
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term PDE5 inhibition (PDE5 inhibitors)
Trial: 27855624
Drug: Estrogen receptor
RxNorm normalized name: Estrogen receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen receptor modulation with PDE5 inhibitors
Trial: 27855998
Drug: Teduglutide 0.0125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teduglutide 0.0125 mg/kg/d
Trial: 27855998
Drug: Teduglutide 0.025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teduglutide 0.025 mg/kg/d
Trial: 27856405
Drug: mHealth technology
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mHealth technology (computer tablet)
Trial: 27856405
Drug: Home visitor-administered,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home visitor-administered, paper-based method
Trial: 27856480
Drug: Pharmacological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological treatment (ON)
Trial: 27856480
Drug: No pharmacological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No pharmacological treatment (OFF)